FindTrial
Sign In

A randomized, blank controlled, open clinical study of EGCG in patients with non-alcoholic fatty liver disease

EGCG inhibits the interaction between DPP4 and PRDM10 to improve the occurrence and development of non-alcoholic fatty liver disease and its mechanism

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300076741
Enrollment
Unknown
Registered
2023-10-17
Start date
2023-11-01
Completion date
Unknown
Last updated
2023-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-alcoholic fatty liver disease

Interventions

EGCG treatment group:EGCG
Blank control group:None

Sponsors

the First Affiliated Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Patients with fatty liver identified by ultrasound examination of the liver

Exclusion criteria

Exclusion criteria: (1) more than 140 grams of alcohol per week for men and 70 grams per week for women; (2) A history of viral hepatitis, autoimmune hepatitis, or other forms of chronic liver disease; (3) Self-reported acute infection within 2 weeks; (4) Body mass index (BMI) less than 18.0 kg/m2

Design outcomes

Primary

MeasureTime frame
liver fat content;—

Secondary

MeasureTime frame
DPP-4;PRDM10;FAS;Fasting blood glucose concentration;serum cholesterol level;serum triglyceride level;HDL-C;Fasting serum insulin levels;HbA1c;—

Countries

China

Contacts

Public ContactYanli Cao

the First Affiliated Hospital of China Medical University

vanilla421@163.com+86 159 4036 8610

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026